Oruka Therapeutics, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Oruka Therapeutics, Inc. (ORKA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $5.00 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2026-03-12
- 2024-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $5.00M.
- 2024-08-29: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $5.00M.
- 2009-01-27: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $37.20M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2024-09-30 | $5.00M 10-Q · filed 2024-11-13 |
| 2024-08-29 | $5.00M 10-K · filed 2026-03-12 |
| 2009-01-27 | $37.20M 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |